Published in Drugs on January 01, 1992
Testing of serum atherogenicity in cell cultures: questionable data published. Ger Med Sci (2012) 0.89
Hormesis and homeopathy: The artificial twins. J Intercult Ethnopharmacol (2014) 0.79
Soy and phytoestrogens: possible side effects. Ger Med Sci (2014) 0.77
HHF35, a muscle-actin-specific monoclonal antibody. I. Immunocytochemical and biochemical characterization. Am J Pathol (1987) 2.91
Comparison of nifedipine, propranolol and isosorbide dinitrate on angiographic progression and regression of coronary arterial narrowings in angina pectoris. Am J Cardiol (1989) 0.96
Evidence of antiatherosclerotic action of verapamil from direct effects on arterial cells. Am J Cardiol (1987) 0.92
Primary culture of human aortic intima cells as a model for testing antiatherosclerotic drugs. Effects of cyclic AMP, prostaglandins, calcium antagonists, antioxidants, and lipid-lowering agents. Atherosclerosis (1986) 0.86
Vascular protection from atherosclerosis: potential of calcium antagonists. Am J Cardiol (1990) 0.84
Blood serum atherogenicity associated with coronary atherosclerosis. Evidence for nonlipid factor providing atherogenicity of low-density lipoproteins and an approach to its elimination. Circ Res (1988) 0.83
Atherogenicity of blood serum from patients with coronary heart disease. Lancet (1986) 0.83
Cardiovascular drugs and atherosclerosis: effects of calcium antagonists, beta-blockers, and nitrates on atherosclerotic characteristics of human aortic cells. J Cardiovasc Pharmacol (1988) 0.83
Correlation between cholesterol content in circulating immune complexes and atherogenic properties of CHD patients' serum manifested in cell culture. Atherosclerosis (1990) 0.81
In vitro models of anti-atherosclerotic effects of cardiovascular drugs. Am J Cardiol (1990) 0.79
Adult human aortic cells in primary culture: heterogeneity in shape. Heart Vessels (1986) 0.79
Triggerlike stimulation of cholesterol accumulation and DNA and extracellular matrix synthesis induced by atherogenic serum or low density lipoprotein in cultured cells. Circ Res (1990) 0.79
Low density lipoprotein-containing circulating immune complexes and coronary atherosclerosis. Exp Mol Pathol (1990) 0.78
Lipids in cells of atherosclerotic and uninvolved human aorta. I. Lipid composition of aortic tissue and enzyme-isolated and cultured cells. Exp Mol Pathol (1985) 0.77
Atherogenic effects of beta blockers on cells cultured from normal and atherosclerotic aorta. Am J Cardiol (1988) 0.76
Hemodynamic, antivasoconstrictor, and antiatherosclerotic effects of calcium antagonists in animal models of atherosclerosis. J Cardiovasc Pharmacol (1990) 0.75
Calcium channel blockers and atherosclerosis. J Cardiovasc Pharmacol (1990) 0.75
Cholesterol level in circulating immune complexes as a marker of coronary atherosclerosis. Adv Exp Med Biol (1991) 0.75
Cellular composition of atherosclerotic and uninvolved human aortic subendothelial intima. Light-microscopic study of dissociated aortic cells. Am J Pathol (1984) 0.94
Desialylated low density lipoprotein--naturally occurring modified lipoprotein with atherogenic potency. Atherosclerosis (1991) 0.93
Modification of low density lipoprotein by desialylation causes lipid accumulation in cultured cells: discovery of desialylated lipoprotein with altered cellular metabolism in the blood of atherosclerotic patients. Biochem Biophys Res Commun (1989) 0.92
Lipoprotein aggregation as an essential condition of intracellular lipid accumulation caused by modified low density lipoproteins. Biochem Biophys Res Commun (1989) 0.92
Evidence of antiatherosclerotic action of verapamil from direct effects on arterial cells. Am J Cardiol (1987) 0.92
[Variability of intima-media thickness of the common carotid arteries in Moscow city population without clinical symptoms of atherosclerosis]. Ter Arkh (2011) 0.91
Conformation of apolipoprotein E both in free and in lipid-bound form may determine the avidity of triglyceride-rich lipoproteins to the LDL receptor: structural and kinetic study. Biochim Biophys Acta (2000) 0.91
The atherogenic effect of lupus sera: systemic lupus erythematosus-derived immune complexes stimulate the accumulation of cholesterol in cultured smooth muscle cells from human aorta. Clin Immunol Immunopathol (1992) 0.89
Dissociated cells from different layers of adult human aortic wall. Acta Anat (Basel) (1984) 0.89
Hydrolysis of cholesteryl ester in low density lipoprotein converts this lipoprotein to a liposome. J Biol Chem (1992) 0.88
Direct anti-atherosclerosis-related effects of garlic. Ann Med (1995) 0.88
Primary culture of human aortic intima cells as a model for testing antiatherosclerotic drugs. Effects of cyclic AMP, prostaglandins, calcium antagonists, antioxidants, and lipid-lowering agents. Atherosclerosis (1986) 0.86
Carbohydrate composition of protein and lipid components in sialic acid-rich and -poor low density lipoproteins from subjects with and without coronary artery disease. J Lipid Res (1993) 0.86
Three types of naturally occurring modified lipoproteins induce intracellular lipid accumulation due to lipoprotein aggregation. Circ Res (1992) 0.86
Trapidil derivatives as potential antiatherosclerotic drugs. Arzneimittelforschung (1987) 0.86
Low-density lipoprotein modification occurring in human plasma possible mechanism of in vivo lipoprotein desialylation as a primary step of atherogenic modification. Atherosclerosis (1998) 0.85
Characteristics of low-density lipoprotein subfractions from patients with coronary artery disease. Coron Artery Dis (1993) 0.85
Autoantibodies against modified low density lipoprotein. Nonlipid factor of blood plasma that stimulates foam cell formation. Arterioscler Thromb (1991) 0.85
Dibutyryl cyclic AMP decreases proliferative activity and the cholesteryl ester content in cultured cells of atherosclerotic human aorta. Biochem Biophys Res Commun (1982) 0.85
[Direct antiatherosclerotic therapy: possible approaches, results of clinical trials]. Patol Fiziol Eksp Ter (2014) 0.84
Intimal cells and atherosclerosis. Relationship between the number of intimal cells and major manifestations of atherosclerosis in the human aorta. Am J Pathol (1986) 0.84
Activity of Tissue Factor in Microparticles Produced in vitro by Endothelial Cells, Monocytes, Granulocytes, and Platelets. Biochemistry (Mosc) (2016) 0.84
Stable analogues of prostacyclin and thromboxane A2 display contradictory influences on atherosclerotic properties of cells cultured from human aorta. The effect of calcium antagonists. Atherosclerosis (1988) 0.84
Human plasma trans-sialidase causes atherogenic modification of low density lipoprotein. Atherosclerosis (2001) 0.83
Autoantibodies against low-density lipoprotein and atherogenic potential of blood. Ann Med (1993) 0.83
Atherogenicity of blood serum from patients with coronary heart disease. Lancet (1986) 0.83
Blood serum atherogenicity associated with coronary atherosclerosis. Evidence for nonlipid factor providing atherogenicity of low-density lipoproteins and an approach to its elimination. Circ Res (1988) 0.83
[Study of intima-medial thickness (IMT) of the carotid arteries as an indicator of natural atherosclerosis progress in Moscow population]. Patol Fiziol Eksp Ter (2012) 0.83
Lipoprotein immune complexes as markers of atherosclerosis. Int J Tissue React (1991) 0.83
Cardiovascular drugs and atherosclerosis: effects of calcium antagonists, beta-blockers, and nitrates on atherosclerotic characteristics of human aortic cells. J Cardiovasc Pharmacol (1988) 0.83
Isolation of atherogenic modified (desialylated) low density lipoprotein from blood of atherosclerotic patients: separation from native lipoprotein by affinity chromatography. Biochem Biophys Res Commun (1990) 0.82
Sialic acid content of human low density lipoproteins affects their interaction with cell receptors and intracellular lipid accumulation. J Lipid Res (1992) 0.81
Modified low density lipoprotein from diabetic patients causes cholesterol accumulation in human intimal aortic cells. Atherosclerosis (1993) 0.81
Multiple-modified desialylated low density lipoproteins that cause intracellular lipid accumulation. Isolation, fractionation and characterization. Lab Invest (1992) 0.80
Naturally occurring modified low density lipoproteins are similar if not identical: more electronegative and desialylated lipoprotein subfractions. Exp Mol Pathol (1995) 0.80
[Cholesterol of circulating immune complexes as biomarker of atherosclerosis]. Patol Fiziol Eksp Ter (2012) 0.80
Contents of mRNAs encoding endosome/lysosome components in normal human aorta and in stage II of atherogenesis: a hidden regulation. Biochemistry (Mosc) (2011) 0.80
Antiatherogenic effect of grape flavonoids in an ex vivo model. Bull Exp Biol Med (2006) 0.80
Characteristics of low density lipoprotein isolated from circulating immune complexes. Atherosclerosis (1996) 0.79
Optimization of the assay for sialic acid determination in low density lipoprotein. J Lipid Res (1998) 0.79
Diagnostic value of immune cholesterol as a marker for atherosclerosis. J Cardiovasc Risk (1995) 0.79
Vascular signal transduction and atherosclerosis. Ann N Y Acad Sci (1990) 0.79
[Anti-atherosclerotic properties of higher mushrooms (a clinico-experimental investigation)]. Vopr Pitan (1989) 0.79
In vitro effect of garlic powder extract on lipid content in normal and atherosclerotic human aortic cells. Lipids (1997) 0.79
Triggerlike stimulation of cholesterol accumulation and DNA and extracellular matrix synthesis induced by atherogenic serum or low density lipoprotein in cultured cells. Circ Res (1990) 0.79
Low density lipoprotein-containing circulating immune complexes and coronary atherosclerosis. Exp Mol Pathol (1990) 0.78
[Atherogenic cholesterol-containing circulating immune complexes--one of the components of the serum in patients with systemic lupus erythematosus]. Klin Med (Mosk) (2003) 0.78
[Circulating immune complex cholesterol as a biochemical marker of coronary atherosclerosis]. Kardiologiia (1991) 0.78
Artificial HDL as an anti-atherosclerotic drug. Lancet (1984) 0.78
Beta-blockers: propranolol, metoprolol, atenolol, pindolol, alprenolol and timolol, manifest atherogenicity on in vitro, ex vivo and in vivo models. Elimination of propranolol atherogenic effects by papaverine. Atherosclerosis (1992) 0.78
Content and localization of fibronectin in normal intima, atherosclerotic plaque, and underlying media of human aorta. Atherosclerosis (1984) 0.78
Characterization of desialylated low-density lipoproteins which cause intracellular lipid accumulation. Int J Tissue React (1992) 0.78
Structural peculiarities of the binding of very low density lipoproteins and low density lipoproteins to the LDL receptor in hypertriglyceridemia: role of apolipoprotein E. Biochim Biophys Acta (2000) 0.78
Atherogenicity of autoantibodies against low density lipoprotein. Agents Actions (1991) 0.77
[Allicor efficacy in lowering the risk of ischemic heart disease in primary prophylaxis]. Ter Arkh (2005) 0.77
Diabetes mellitus and atherosclerosis. N Engl J Med (1987) 0.77
Regression of atherosclerotic manifestations in primary culture of human aortic cells: effects of prostaglandins. Biomed Biochim Acta (1984) 0.77
Lipids in cells of atherosclerotic and uninvolved human aorta. I. Lipid composition of aortic tissue and enzyme-isolated and cultured cells. Exp Mol Pathol (1985) 0.77
Antibody-like immunoglobulins G against low density lipoprotein that stimulate lipid accumulation in cultured cells. Adv Exp Med Biol (1991) 0.77
Lipids in cells of atherosclerotic and uninvolved human aorta. II. Lipid metabolism in primary culture. Exp Mol Pathol (1985) 0.77
Insolubilization of low density lipoprotein induces cholesterol accumulation in cultured subendothelial cells of human aorta. Atherosclerosis (1989) 0.77
The effects of antihypertensive agents on atherosclerosis-related parameters of human aorta intimal cells. Cardiology (1998) 0.77
[Effect of long-acting garlic tablets "allicor" on the incidence of acute respiratory viral infections in children]. Ter Arkh (2003) 0.76
Lipid accumulation in the subendothelial cells of human aortic intima impairs cell-to-cell contacts: A comparative study in situ and in vitro. Cardiovasc Pathol (2015) 0.76
Atherogenic effects of beta blockers on cells cultured from normal and atherosclerotic aorta. Am J Cardiol (1988) 0.76
[Use of allicor to lower the risk of myocardial infarction]. Klin Med (Mosk) (2007) 0.76
Modified (desialylated) low-density lipoprotein measured in serum by lectin-sorbent assay. Clin Chem (1995) 0.76
Use of natural products in anticytokine therapy. Bull Exp Biol Med (2007) 0.76
Similarity between naturally occurring modified desialylated, electronegative and aortic low density lipoprotein. Free Radic Res (1996) 0.76
Characterization of chemical composition of native and modified low density lipoprotein occurring in the blood of diabetic patients. Int Angiol (1994) 0.76
Deglycosylation of apo B-containing lipoproteins increase their ability to aggregate and to promote intracellular cholesterol accumulation in vitro. Arch Physiol Biochem (2008) 0.76
Determination of total intracellular lipid content by flow cytofluorometry. Biochem Biophys Res Commun (1985) 0.76
Effect of sex hormones on levels of mRNAs coding for proteins involved in lipid metabolism in macrophages. Biochemistry (Mosc) (2013) 0.76
[Evaluation of the antiatherosclerotic properties of natural compounds of plant origin on cell cultures of the human aortic intima]. Farmakol Toksikol (1990) 0.75
A study of rat liver guanylate cyclase activation by peroxides of fatty acids, carbonyl compounds and biogenic amines. Biochim Biophys Acta (1983) 0.75
Degradation of human apolipoprotein B-100 by apolipoprotein(a). FEBS Lett (1993) 0.75
Are all low-density lipoprotein particles partially desialylated in plasma? Atherosclerosis (1999) 0.75
Synergetic effect of desialylated and glycated low density lipoproteins on cholesterol accumulation in cultured smooth muscle intimal cells. Atherosclerosis (1991) 0.75
Antioxidant content in low density lipoprotein and lipoprotein oxidation in vivo and in vitro. Free Radic Res (1998) 0.75
Atherogenic modified LDL in diabetes. Diabetes (1996) 0.75
Phospholipid hydrolysis with phospholipases A2 and C impairs apolipoprotein B-100 conformation on the surface of low density lipoproteins by reducing their association resistance. Bull Exp Biol Med (2005) 0.75
[Cultured cell systems for revelation of new drugs antiatherosclerotic effects and their mechanisms investigation]. Patol Fiziol Eksp Ter (2012) 0.75
Low ionic strength promotes association of circulating modified LDL in human blood. Bull Exp Biol Med (2004) 0.75
[Effect of ionizing radiation on the activity of adenylate cyclase, cAMP phosphodiesterase and the level of cAMP in mouse liver]. Dokl Akad Nauk SSSR (1977) 0.75
Desialylation decreases the resistance of apo B-containing lipoproteins to aggregation and increases their atherogenic potential. Bull Exp Biol Med (2005) 0.75
Resistance of native and circulating modified low-density lipoproteins in human blood to association. Bull Exp Biol Med (2004) 0.75
Coordination in gene expression during atherogenesis. Biochemistry (Mosc) (2013) 0.75
Effect of plant extracts on trans-sialidase activity in human blood plasma. Bull Exp Biol Med (2007) 0.75
Changes in levels of gene expression in human aortal intima during atherogenesis. Biochemistry (Mosc) (2013) 0.75
[Reduction of cardiovascular risk in primary prophylaxy of coronary heart disease]. Klin Med (Mosk) (2005) 0.75
[Interaction of native and modified low density lipoprotein with intimal cells in atherosclerotic lesion]. Patol Fiziol Eksp Ter (2013) 0.75
Oxidation-induced aggregation of LDL increases their uptake by smooth muscle cells from human aorta. Bull Exp Biol Med (2007) 0.75
Pluronics suppress association of low-density lipoproteins inducing atherogenesis. Bull Exp Biol Med (2014) 0.75
Proteolysis of apoprotein B-100 impairs its topography on LDL surface and reduces LDL association resistance. Bull Exp Biol Med (2005) 0.75